Employees: 02 (2023.0)Legal category: 5785Size: PMECreation date: 2019-01-01 (7 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: BORDEAUX (33000), Gironde
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE DU GRAND LEBRUN : revenue, balance sheet and financial ratios
PHARMACIE DU GRAND LEBRUN is a French company
founded 7 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in BORDEAUX (33000),
this company of category PME
shows in 2022 a revenue of 3.1 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DU GRAND LEBRUN (SIREN 844934620)
Indicator
2024
2023
2022
2021
2020
2019
Revenue
N/C
N/C
3 118 786 €
N/C
N/C
N/C
Net income
53 971 €
60 178 €
164 248 €
94 796 €
81 090 €
6 410 €
EBITDA
N/C
N/C
221 402 €
N/C
N/C
N/C
Net margin
N/C
N/C
5.3%
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE DU GRAND LEBRUN generates positive net income of 54 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2024: 6 k€ -> 54 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
53 971 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 229%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 26%. The balance between equity and debt is satisfactory.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
228.993%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
26.257%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DU GRAND LEBRUN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Debt ratio
552.268
444.65
353.094
329.775
274.861
228.993
Financial autonomy
13.499
16.449
19.053
20.398
23.364
26.257
Repayment capacity
None
None
None
19.338
None
None
Cash flow / Revenue
None%
None%
None%
3.426%
None%
None%
Sector positioning
Debt ratio
228.992024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average
In 2024, the debt ratio of PHARMACIE DU GRAND LEBRUN (228.99) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
26.26%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Watch
In 2024, the financial autonomy of PHARMACIE DU GRAND LEBRUN (26.3%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
Repayment capacity
19.34 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Watch
In 2022, the repayment capacity of PHARMACIE DU GRAND LEBRUN (19.34) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 88.92. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
88.919
Liquidity indicators evolution PHARMACIE DU GRAND LEBRUN
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2019
2020
2021
2022
2023
2024
Liquidity ratio
160.203
169.586
148.604
82.957
122.461
88.919
Interest coverage
None
None
None
19.72
None
None
Sector positioning
Liquidity ratio
88.922024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Watch
In 2024, the liquidity ratio of PHARMACIE DU GRAND LEBRUN (88.92) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
19.72x2022
2022
Q1: 0.74x
Med: 2.5x
Q3: 5.15x
Excellent
In 2022, the interest coverage of PHARMACIE DU GRAND LEBRUN (19.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DU GRAND LEBRUN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
72 637 €
0 €
0 €
Inventory turnover (days)
0
0
0
28
0
0
Customer payment term (days)
0
0
0
5
0
0
Supplier payment term (days)
0
0
0
24
0
0
Positioning of PHARMACIE DU GRAND LEBRUN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE DU GRAND LEBRUN is estimated at
753 475 €
(range 524 708€ - 1 127 241€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
524k€753k€1127k€
753 475 €Range: 524 708€ - 1 127 241€
NAF 5 année 2024
Valuation method used
Net Income Multiple
53 971 €
×
14.0x
=753 475 €
Range: 524 708€ - 1 127 242€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DU GRAND LEBRUN with other companies in the same sector:
Frequently asked questions about PHARMACIE DU GRAND LEBRUN
What is the revenue of PHARMACIE DU GRAND LEBRUN ?
The revenue of PHARMACIE DU GRAND LEBRUN in 2022 is 3.1 M€.
Is PHARMACIE DU GRAND LEBRUN profitable?
Yes, PHARMACIE DU GRAND LEBRUN generated a net profit of 54 k€ in 2024.
Where is the headquarters of PHARMACIE DU GRAND LEBRUN ?
The headquarters of PHARMACIE DU GRAND LEBRUN is located in BORDEAUX (33000), in the department Gironde.
Where to find the tax return of PHARMACIE DU GRAND LEBRUN ?
The tax return of PHARMACIE DU GRAND LEBRUN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DU GRAND LEBRUN operate?
PHARMACIE DU GRAND LEBRUN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart